
Kaia Health is a leading digital therapeutics company specializing in evidence-based treatments for musculoskeletal pain and chronic conditions. Their innovative platform combines AI-driven personalized therapy with human support, offering users access to licensed physical therapists and certified coaches. With over 560,000 participants and around 2,000 clients in the U.S., Kaia Health is recognized for its effective digital-first approach, which has resulted in significant pain reduction and improved sleep quality for users. The company aims to make effective therapy accessible to millions, positioning itself as a market leader in digital musculoskeletal care globally.

Kaia Health is a leading digital therapeutics company specializing in evidence-based treatments for musculoskeletal pain and chronic conditions. Their innovative platform combines AI-driven personalized therapy with human support, offering users access to licensed physical therapists and certified coaches. With over 560,000 participants and around 2,000 clients in the U.S., Kaia Health is recognized for its effective digital-first approach, which has resulted in significant pain reduction and improved sleep quality for users. The company aims to make effective therapy accessible to millions, positioning itself as a market leader in digital musculoskeletal care globally.
What they do: Digital therapeutics delivering AI-powered multimodal programs for musculoskeletal pain and COPD
Founding: Founded 2016; headquartered in Munich and New York
Scale: Reported ~560,000 participants and ~2,000 U.S. clients
Funding: Reported total funding ~$123M with a $75M Series C in Apr 2021
Musculoskeletal pain and chronic respiratory disease (COPD); reducing pain and improving function/sleep via digital therapy.
2016
Digital therapeutics / Healthtech
$10,000,000
Reported Series A announced January 21, 2019
$26,000,000
Reported Series B announced June 18, 2020
$75,000,000
Reported Series C announced April 28, 2021
$8,000,000
Reported $8M round announced September 17, 2019
“Participation from strategic health and growth investors including Optum Ventures, Eurazeo, Balderton Capital, Heartcore Capital, Idinvest, capital300, 3VC”